Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations
Author(s): Okeke Claudia C, Medwick Thomas, Nairn Graham, Shaila Khuspe, Grady Lee T
Issue: Jul/Aug 2003 - After the Women's Health Initiative Trial
View All Articles in Issue
Page(s): 313-319
Download in electronic PDF format for $65
Abstract: The objective of this study was to evaluate the chemical stability of hydralazine
hydrochloride 0.1% and 1% when prepared extemporaneously from commercially
available hydralazine bulk powder. The oral solutions were prepared to contain
preservatives, sweeteners, a humectant and diluting agents. They were prepared
flavored and nonflavored and stored in duplicate glass and plastic bottles. Each of
the flavored preparations was stored at 5°C, 25°C/60% relative humidity and
40°C/75% relative humidity. Samples from the bottles of concentrations stored
under these conditions were taken for a period of up to 92 days. Each of the nonflavored
preparations was stored at 5°C. Samples from the bottles stored under
these conditions were taken for a period of up to 72 days. Samples were taken
from glass and plastic bottles on the designated sampling days for both flavored
and nonflavored preparations, and the samples were analyzed for drug concentration
using a stability-indicating high-pressure liquid chromatography analytical
technique. Degradation occurred faster in the 0.1% oral solution than in the 1%
solution at all the studied conditions. At 40°C, a considerable amount of drug
loss was observed for both the 0.1% and the 1% oral solutions for the flavored
preparations. For both flavored and nonflavored preparations, the lowest studied
temperature condition (5°C) appeared to be the most favorable for the preparations,
with 93% or more of the initial potency retained by day 29.
Related Keywords:
Hydralazine hydrochloride, stability of, Stability of hydralazine hydrochloride
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations
Okeke Claudia C, Medwick Thomas, Nairn Graham, Shaila Khuspe, Grady Lee T
|
Jul/Aug 2003
Pg. 313-319
|
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
|
May/Jun 2020
Pg. 252-262
|
Hydralazine Hydrochloride 10 mg/mL Oral Liquid
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 323-324
|
Hydralazine Hydrochloride 1-mg/mL or 10-mg/mL Oral Liquid
Allen Loyd V Jr
|
Nov/Dec 2006
Pg. 457
|
Hydralazine Hydrochloride 20-mg/mL Injection
Allen Loyd V Jr
|
Jan/Feb 2015
Pg. 65
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes
Xu Quanyun A, Trissel Lawrence A, Pham Lien
|
Jan/Feb 2002
Pg. 66-69
|
Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Bupivacaine Hydrochloride Packaged in Plastic Syringes
Trissel Lawrence A, Xu Quanyun A, Pham Lien
|
Jan/Feb 2002
Pg. 70-73
|
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S, Thyangarajapuram N
|
Sep/Oct 2003
Pg. 389-393
|
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
|
Nov/Dec 2018
Pg. 516-526
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration
Trissel Lawrence A, Xu Quanyun A
|
May/Jun 2005
Pg. 238-241
|